Compare MNMD & CMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNMD | CMP |
|---|---|---|
| Founded | 2019 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 781.2M |
| IPO Year | N/A | 2003 |
| Metric | MNMD | CMP |
|---|---|---|
| Price | $14.94 | $23.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $30.33 | $21.50 |
| AVG Volume (30 Days) | ★ 2.3M | 548.7K |
| Earning Date | 03-05-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,243,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.32 |
| 52 Week Low | $4.70 | $8.60 |
| 52 Week High | $15.29 | $23.66 |
| Indicator | MNMD | CMP |
|---|---|---|
| Relative Strength Index (RSI) | 64.84 | 71.19 |
| Support Level | $12.88 | $21.69 |
| Resistance Level | $15.20 | $23.10 |
| Average True Range (ATR) | 0.92 | 0.88 |
| MACD | 0.11 | 0.27 |
| Stochastic Oscillator | 85.91 | 87.47 |
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.